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Mycobacterium tuberculosis drug resistance (DR) challenges effective tuberculosis disease control. Current molecular
tests examine limited numbers of mutations, and although whole genome sequencing approaches could fully
characterise DR, data complexity has restricted their clinical application. A library (1,325 mutations) predictive of DR
for 15 anti-tuberculosis drugs was compiled and validated for 11 of them using genomic-phenotypic data from 792
strains. A rapid online ‘TB-Profiler’ tool was developed to report DR and strain-type profiles directly from raw sequences.
Using our DR mutation library, in silico diagnostic accuracy was superior to some commercial diagnostics and
alternative databases. The library will facilitate sequence-based drug-susceptibility testing.Background
Resistance has been reported to all drugs used to treat
tuberculosis (TB) [1]. Increased resistance is associated
with decreased patient survival and is a substantial threat
to disease control. The World Health Organization
(WHO) classifies tuberculosis resistant to isoniazid and ri-
fampicin as multi drug-resistant (MDR-TB), when a
switch to second line treatment is advised. Resistance to
additional drugs further compromises treatment success
[2]. MDR-TB strains that have developed resistance to the
fluoroquinolones and aminoglycosides are classed as ex-
tensively drug resistant (XDR-TB). The term totally drug
resistant (TDR-TB) has been used to describe strains
found resistant to all available drugs, but there is not yet
an agreed definition of TDR-TB [1]. Treatment of drug re-
sistant disease is prolonged and expensive, and outcomes
are poor [2,3]. Treatment involves drugs of heightened
toxicity and adverse reactions are common and may be se-
vere and irreversible [4,5]. Poor tolerance leads to reduced
compliance, which in turn reduces cure rates and can re-
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unless otherwise stated.Early detection is crucial for access to effective treat-
ment and prevention of onward transmission. Know-
ledge of the full drug susceptibility profile would enable
tailored treatment to improve efficacy and reduce expos-
ure to ineffective toxic drugs. Current testing for resist-
ance to most anti-TB drugs involves isolation and
culture of the bacteria followed by exposure to the drug,
a process that takes weeks or months and requires high
levels of microbiological safety. The primary cause of re-
sistance in M. tuberculosis is the accumulation of point
mutations and insertions and deletions (indels) in genes
coding for drug-targets or -converting enzymes [7].
Rapid molecular assays that test directly from sputum
are available for some key drugs. In 2013 the Xpert
MTB/RIF (Cepheid, Inc., Sunnyvale, CA, USA), was
granted US FDA approval for detecting resistance to ri-
fampicin, conditional on confirmatory testing [8]. This
easy to use semi-automated PCR-based test has also
been endorsed by WHO, as have Line Probe Assays
(LPA) for resistance to rifampicin and isoniazid, where,
following amplification of bacterial DNA, samples are
interrogated with a panel of oligonucleotide probes [9].
LPA to detect resistance to other drugs, including fluor-
oquinolones and aminoglycosides, have also been devel-
oped [10], but have yet to be endorsed by WHO.
Though undoubtedly useful, both technologies are lim-
ited in the number of loci they examine and they lackis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of mutations included in the curated
whole genome drug resistance library
Drug Loci No. variable sites SNPs Indels
INH katG 241 286 25
katG promoter 3 3 0
inhA 12 15 0
inhA promoter 9 11 0
ahpC 8 8 0
ahpC promoter 13 14 0
kasA 8 11 0
RMP rpoB 89 135 19
rpoC 8 8 0
EMB embB 123 153 1
embA 5 5 0
embA promoter 3 3 0
embC 25 26 0
embR 22 24 0
STR rrs 21 25 0
rpsL 14 19 0
PZA pncA 215 269 64
pncA promoter 4 6 0
rpsA 3 4 0
panD 9 11 1
ETH ethA 33 29 5
ethR 3 4 0
inhA promoter 3 3 0
inhA 3 3 0
FLQs gyrA 15 22 0
gyrB 22 29 0
AMK rrs 8 9 0
CAP rrs 3 4 0
tlyA 26 18 10
KAN rrs 3 4 0
eis promoter 9 10 0
PAS thyA 23 17 5
folC 16 19 0
ribB 1 1 0
LZD rrl 2 2 0
rplC 1 1 0
BDQ CFZ Rv0678 7 5 2
AMK, amikacin; BDQ, bedaquiline; CAP, capreomycin; CFZ, clofazimine; EMB,
ethabutol; ETH, ethionamide; FLQs, fluoroquinolones; INH, isoniazid; KAN,
kanamycin; LZD, linezolid; PAS, para-aminosalycylic acid; PZ, pyrazinamide;
RMP, rifampicin; STR, streptomycin.
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effect drug efficacy, leading to false positive results
[11-13]. Whole genome sequencing has the potential to
overcome such problems and extend rapid testing to the
full range of anti-TB drugs and has been applied in a
clinical setting. Bench top analysers have been developed
capable of sequencing a bacterial genome in a few hours
and costs have been greatly reduced with the introduc-
tion of high throughput technology. Sequencing already
assists patient management for a number of conditions
such as HIV for which Sanger sequencing is performed
to determine viral tropism and drug susceptibility [14].
Recent reports of sequencing M. tuberculosis from spu-
tum from suspected XDR-TB patients suggests it has a
role in the management of TB [15-17]. However, data
analysis remains a bottleneck, requiring specialist expert-
ise not readily available in clinical laboratories. To ad-
dress this issue and progress sequencing towards real
time management of patients we have compiled an ex-
haustive library of 1,325 drug resistance markers and de-
veloped an online tool that rapidly analyses raw
sequence data and predicts resistance. We present ac-
curacy data comparing in silico whole genome analysis
for resistance to 11 anti-TB drugs, to conventional drug
susceptibility testing (DST). To further assess potential
benefits of the whole genome approach we compared
our curated mutation database to two others
(TBDreaMDB and MUBII-TB-DB), as well as those used
in three commercial molecular tests, the Xpert MTB/RIF
(Cepheid, Inc., Sunnyvale, CA, USA), and the MTBDRplus
and MTBDRsl (Hain Life Science, Germany). In particular,
in silico versions of the three commercial molecular tests
were implemented.
Methods
Mutation library
Following review of available data, a library of mutations
predictive of drug resistance was compiled. First, muta-
tions from two publically available web-based tools
TBDreaMDB [18] and MUBII-TB-DB [19] were ex-
tracted. Second, phylogenetic SNPs at drug resistance
loci were removed (see Additional file 1: Table S2 for the
full list), as they have been historically misclassified as
drug resistance markers [20,21]. And third, recent literature
was consulted to include mutations and loci not described
in TBDreaMDB and MUBII-TB-DB. (See Additional file 1:
Table S1 for a list of source materials). Drugs included
were amikacin (AMK), capreomycin (CAP), ethambutol
(EMB), ethionamide (ETH), isoniazid (INH), kanamycin
(KAN), moxifloxacin (MOX), ofloxacin (OFX), pyrazi-
namide (PZA), rifampicin (RMP), streptomycin (STR),
para-aminosalicylic acid (PAS), linezolid (LZD), clofazi-
mine (CFZ) and bedaquiline (BDQ). As presented in
Table 1, the library comprised 1,325 polymorphisms(SNPs and indels) at 992 nucleotide positions from 31
loci, six promoters and 25 coding regions (see [22] for
full list). In addition to examining individual drugs we
considered the cumulative loci for MDR- and XDR-TB.
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omic region variation maps. Polymorphisms associated
with MDR- and XDR-TB are shown in Figure 1 (See
Additional file 1: Figure S1 for full details).
Sequence data and drug susceptibility testing
The precision of the curated library for predicting resist-
ance was assessed through analysis of new and published
sequence data. In silico inferred resistance phenotypes
were compared to phenotypes derived from conven-
tional culture-based methods with the exception of PAS,
LZD, CFZ and BDQ, for which insufficient phenotypic
DST were available for comparison. Six geographically
distinct datasets were used: China (n = 161) [24],
Karachi, Pakistan (n = 42) [25], Karonga District, Malawi
(n = 337) [26], Lisbon and Porto, Portugal (n = 208)
[27], Samara, Russia [28] (n = 21) and Vancouver,
Canada (n = 19) [29] (See Additional file 1: Table S3).
Strains used in the study are a convenience sample and
do not necessarily reflect the population at the site of
collection. All collections had Illumina raw sequencing
data (minimum read length 50 bp) and drug susceptibil-
ity data from recognised testing protocols [30]. Where
conventional susceptibility data was not available, sam-
ples were excluded from analysis for that drug. Sensitiv-
ity, specificity and diagnostic accuracy (area under theFigure 1 Polymorphism in the curated library used for predicting multi-dru
Polymorphisms associated with MDR-TB. (B) Polymorphisms associated with X
to be involved in drug resistance (from Table 1). On top of each of these bars
of polymorphic sites within windows of 20 bp) derived from the curated list o
DR-associated regions in candidate genes, which in some cases span the who
gene (for example, rpoB). Vertical black lines indicate the frequency of mutatio
phenotypically resistance isolates. Internal black lines show co-occurring muta
proportional to the frequency of the mutations appearing together.receiver operating characteristic curve) were estimated
using the phenotypic drug susceptibility test result as
the reference standard [31]. P values and confidence in-
tervals were determined using binomial distribution
approximations.
Rapid mutation detection and the TB Profiler Online tool
To rapidly characterise mutations from whole genome
sequence files (fastq format), we map raw sequences to a
modified version of the H37Rv reference genome (Gen-
bank accession number: NC_000962.3) using the Snap
algorithm [32], and call SNPs and indels using samtool/
vcf tools of high quality (Q30, 1 error per 1,000 bp) as
previously described [21,33]. The modified reference
genome consists of the genes and flanking regional se-
quences containing the 1,325 drug resistance mutations
in the curated list (Table 1) and selected lineage specific
mutations [21]. All high quality SNPs and indels identi-
fied from the alignments are compared to the curated
list to determine known and novel polymorphism. Algo-
rithmic results obtained were compared to standard
SNP calling procedures using the full reference genome
[21]. The online TB Profiler tool [34] was developed in
Perl/PHP. It inputs raw sequence data (fastq format),
identifies drug resistance and lineage specific mutations,
and displays related outputs (see screenshots ing resistant TB (MDR-TB) and extensive-drug resistant TB (XDR-TB). (A)
DR-TB. Colour-coded bars in the Circos plot represent genes described
a grey histogram shows the mutation density (calculated as the number
f DR-associated mutations. These grey areas highlight the presence of
le gene (for example, katG) or are confined to a certain region of the
ns (that is, the number of times the mutation has been observed) in
tions both within and between genes. The thickness of these lines is
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implement the Snap software and samtool/vcf based bio-
informatic pipeline. The script is available from the cor-
responding author.
Comparison with existing tools
To examine the potential analytical advantage of whole
genome sequencing comparison was made with three
commercial tests: (1) the Xpert MTB/RIF (Cepheid Inc.,
USA) which targets the rpoB gene for RMP resistance;
(2) the LPA MTBDRplus for MDR-TB (Hain Lifescience,
Germany) which targets rpoB, katG and inhA for resist-
ance to RMP and INH; and (3) the LPA MTBDRsl
(Hain Lifescience, Germany) which targets gyrA, rrs
and embB for resistance to the fluoroquinolones (FLQ),Figure 2 Inferred analytical accuracies of the whole genome mutation libr
analysis of published sequence data using mutation libraries derived from
MTBDRplus (orange) (Hain Life Sciences, Germany), and the curated whole
phenotypes were compared to reported phenotypes obtained from conve
confidence intervals. Abbreviations: AMK, amikacin; CAP, capreomycin; EMB
multi-drug resistance; MOX, moxifloxacin; OFX, ofloxacin; PZA, pyrazinamideaminoglycosides and ethambutol, respectively. In silico
versions were developed based on the polymorphisms
used by these assays and their performance compared
to the whole genome mutation library. In particular, in
silico analysis of the six datasets was performed and
analytical sensitivities and specificities of the inferred
resistance relative to the reported phenotype were com-
pared (Figure 2, Additional file 1: Figures S3 and S4).
KvarQ [35], a new tool that directly scans fastq files of
bacterial genome sequences for known genetic poly-
morphisms, was run across all 792 samples using the
MTBC test suite and default parameters. Sensitivity
and specificity achieved by this method using pheno-
typic DST results as the reference standard were
calculated.ary and three commercial molecular tests for resistance. In silico
XpertMTB/RIF (Cepheid Inc., USA) (purple), MTBDRsl (red) and
genome library (blue). For each library in silico inferred resistance
ntional drug susceptibility testing. Errors bars correspond to 95%
, ethambutol; ETH, ethionamide; INH, Isoniazid; KAN, kanamycin; MDR,
; RMP, rifampicin; STR, streptomycin; XDR, extensive drug resistance.
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A mutation library
Following review of available data (See Additional file 1:
Table S1 for a list of source materials), a library compris-
ing 1,325 polymorphisms (single nucleotide polymor-
phisms (SNPs) and indels) at 992 nucleotide positions
from 31 loci, six promoters and 25 coding regions was
established. This library covered the anti-TB drugs:
EMB, ETH, INH, PZA, RMP, STR and the second line
drugs used to treat MDR-TB AMK, CAP, KAN, MOX
and OFX. Mutations associated with resistance to PAS,
LZD, CFZ and BDQ were also compiled but were not
included in the analysis given lack of available pheno-
typic DST results. In addition to examining individual
drugs we considered the cumulative loci for MDR- and
XDR-TB. Polymorphisms associated with MDR- and
XDR-TB are shown in Figure 1 (see Additional file 1:
Figure S1 for full details).
Validation of the mutation library
The mutation library was validated using new and publi-
cally available sequence and phenotypic data from 792
isolates, from six countries (Canada, China, Malawi,
Pakistan, Portugal and Russia; see Additional file 1: Table
S3). Of the 792 isolates, 365 (46%) were phenotypically
resistant to at least one drug, 262 (33%) were MDR-TB,
54 (6.8%) XDR-TB and 426 (54%) were susceptible to all
drugs tested. In silico genotyping [36] revealed the major
modern M. tuberculosis lineages were represented, in-
cluding Lineage 1 (East African Indian spoligotype fam-
ily: 68, 8.6%), Lineage 2 (Beijing spoligotype: 182, 23%),
Lineage 3 (Central Asian: 86, 10.9%) and Lineage 4 (456
isolates, 57.5% including 298 LAM, 35 X, 97 T, 4S, 18 H
and 4 other spoligotypes). In silico inferred resistance
from whole genome sequence data was compared to
the reported resistance phenotype from conventional
culture-based susceptibility testing. Results are sum-
marised in Table 2. Sensitivity and specificity varied by
drug, and with the geographic origin (Additional file 1:
Figure S4). For the drugs that contribute to MDR-TB
correlation of mutation analysis with the reported
phenotype was high. Mutations predictive of resistance
were found in 96.0% and 92.8% of samples resistant to
RMP and INH, respectively. Of 22 phenotypically INH
resistant samples not detected by mutation analysis, 14
were from China. Further analysis revealed seven had
mutations in known candidate loci (katG and ahpC
promoter) not previously reported (Additional file 1:
Table S4). No additional cases of INH resistance were
suggested by the genome analysis. However, 10 isolates
reported as susceptible to RMP by conventional testing
had mutations predictive of resistance, six of which
were from Malawi. Correlation was slightly poorer for
other first line drugs. For PZA 32 of 110 samples with aresistant phenotype were not recognised by genome
analysis, including 18 of 37 samples from Karachi.
However, specificity for this drug was high (93%; 95%
CI: 90.6 to 97.2). Correlation was also reduced for EMB
where 61 of 334 susceptible stains were found to
harbour mutations included in the library of resistance
polymorphisms (81.7% specificity). For the aminoglyco-
sides used to treat MDR-TB correlation was higher for
AMK and KAN than for CAP, where 35 of 89 resistant
samples were not detected by the in silico genome ana-
lysis. Testing for fluoroquinolone resistance was less
commonly reported and data for OFX was restricted to
313 samples from two studies (China and Portugal).
Mutations were not identified in 17 resistant samples
(85.5% sensitivity) and 10 drug susceptible samples
were found to harbour mutations associated with resist-
ance (94.9% specificity). Of 42 samples tested for sus-
ceptibility to MOX, 10 were reported as phenotypically
resistant, of which six were recognised by the in silico
mutation analysis.
Comparison with commercial tests and other drug
resistance databases
Having assessed the diagnostic potential of the mutation
library, comparison was made with the polymorphisms
used in commercially available molecular tests for drug
resistance. Results are summarised in Figure 2. There
was no significant difference between the mutation li-
brary and polymorphisms employed by the Xpert MTB/
RIF and the LPA MTBDRplus for detecting resistance to
RMP. However, 31 samples had mutations predictive of
resistance to INH not covered by the MTBDRplus. The
alleles concerned were mainly in the gene encoding
catalase-peroxidase enzyme (katG) (S315N (n = 9),
S315G (n = 1), D419H (n = 1), L378P (n = 1), V1A (n = 1),
Y155C (n = 3), W191R (n = 5 and always with C-15T inhA
promoter), N138D (n = 1, with T-8A inhA promoter) and
T380I (n = 1; with C-15T inhA promoter). There were also
six samples with ahpC promoter mutations and two sam-
ples with inhA mutations (S94A and I194T). No resistance
mutations were observed in INH susceptible strains sug-
gesting 100% specificity. Overall, when screening for
MDR-TB the mutation library offered enhanced accuracy
over the line probe mutations (95.8 vs. 93.1%; P <0.0004)
(Table 2).
Fewer susceptibility data were available for the second
line drugs. For each of the fluoroquinolones and amino-
glycosides the sensitivity of the mutation library was
equal to, or greater than for the mutations employed in
the LPA MTBDRsl (Figure 2), although a slight reduc-
tion in specificity was observed: MOX (71.9 vs. 68.8%,
P <0.32), OFX (95.9 vs. 94.9%, P <0.083), CAP (91.1 vs.
90.7%, P <0.32), KAN (99.0 vs. 93.4%, P <0.001) and
EMB (86.6 vs. 81.7%, P <0.001). Overall when detecting
Table 2 Accuracy of whole genome drug resistance analysis compared to reported resistance phenotype when applied to in silico determination of resistance
from raw sequence data
Drug Sample size Resistant (%) Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI) China
Sen/Spec
Pakistan
Sen/Spec
Malawi
Sen/Spec
Portugal
Sen/Spec
Russia
Sen/Spec
Canada
Sen/Spec
INH 693 305 (44) 92.8 (89.9-95.7) 100 (100–100) 96.8 (95.5-98.1) 88.0/100 100/100 92.6/100 94.6/100 100/100 -/100
RMP 694 264 (38) 96.2 (93.9-98.5) 98.1 (96.8-99.4) 97.4 (96.2-98.5) 95.7/97.7 97.3/100 100/98.2 96.9/100 90.9/90.0 -/100
EMB 484 150 (31) 88.7 (83.6-93.8) 81.7 (77.6-85.8) 83.9 (80.6-87.2) 83.6/71.3 100/42.7 100/80 85.7/68.1 100/80.0 -/100
STR 487 225 (46.2) 87.1 (82.7-91.5) 89.7 (86.0-93.4) 88.5 (85.7-91.3) 86.8/91.0 95.8/44.4 61.5/95.6 86.8/81.5 100/100 -/100
PZA 307 110 (35.8) 70.9 (62.4-79.4) 93.9 (90.6-97.2) 85.7 (81.7-89.6) NT 51.3/- 66.7/94.8 80.6/100 100/60.0 -/100
ETH 334 155 (46.4) 73.6 (66.7-80.5) 93.3 (89.6-97.0) 84.1 (80.2-88.1) 38.9/97.3 66.7/90.3 NT 84.9/84.6 NT NT
MOX 42 10 (23.8) 60.0 (29.6-90.4) 68.7 (52.6-84.8) 66.7 (52.4-80.9) NT NT NT 83.3/56.2 25.0/100 NT
OFX 313 117 (37.4) 85.5 (79.1-91.9) 94.9 (91.8 · 98.0) 91.4 (88.3-94.5) 77.8/95.1 -/100 NT 92.1/93.2 NT NT
AMK 193 76 (39.4) 82.9 (74.4-91.4) 98.3 (96.0-100) 92.2 (88.4-96.0) NT 86.5/100 NT 79.5/98.2 NT NT
CAP 358 89 (24.9) 60.7 (50.6-70.8) 90.7 (87.2-94.2) 83.2 (79.4-87.1) 50.0/97.0 85.7/21.7 NT 57.7/98.0 100/91.7 NT
KAN 118 118 (37.3) 87.3 (81.3-93.3) 93.4 (89.9-96.9) 91.1 (88.0-94.3) 71.4/97.0 83.8/- NT 98.0/88.7 80.0/33.3 NT
MDR 693 262 (37.8) 91.2 (87.8-94.6) 98.4 (97.2-99.6) 95.8 (94.3-97.3) 86.3/100 97.3/100 100/98.2 95.8/100 90.9/90.0 -/100
XDR 601 54 (9) 75.9 (64.5-87.3) 98.4 (97.3-99.5) 96.3 (94.8-97.8) 60.9/99.1 -/100 -/100 96.3/88.9 25.0/100 -/100
AMK, amikacin; CAP, capreomycin; CI, confidence interval; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KAN, kanamycin; MDR, multi-drug resistance; MOX, moxifloxacin; OFX, ofloxacin; NT, not tested;
PZA, pyrazinamide; RMP, rifampicin; Sen, sensitivity; Spec, specificity; STR, streptomycin; XDR, extensive drug resistance.
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Coll et al. Genome Medicine  (2015) 7:51 Page 7 of 10XDR-TB the whole genome analysis offered enhanced ac-
curacy over the line probe assay (96.3 vs. 93.7%; P <0.0047)
(Table 2).
The mutation library was also found to be more accur-
ate than previously reported databases TBDreaMDB and
MUBII-TB-DB (Additional file 1: Figure S3), because of
false positive resistance arising in those databases due to
the inclusion of some phylogenetic (but not drug resist-
ance) informative SNPs. An improvement in sensitivity
was also achieved for INH, EMB, ETH, PZA and KAN
by considering recently discovered drug resistance loci
and polymorphisms (Additional file 1: Figure S3).
When compared to KvarQ [35] the mutation library
achieved higher sensitivity for resistance to isoniazid, pyra-
zinamide, ofloxacin and amikacin with increases of 5.9%,
8.2%, 3.5% and 7.9%, respectively, without compromising
specificity (Additional file 1: Table S5). Higher sensitivity
was also achieved for ethambutol (28%), streptomycin
(7.1%) and kanamycin (33.1%) but with reductions in spe-
cificity (-7.5%, -9.1% and -5.1%, respectively). Sensitivity
and specificity values remained the same or very similar
for rifampicin and moxifloxacin. KvarQ did not predict re-
sistance status for ethionamide and capreomycin.
Online tool for predicting drug resistance and lineage
information from sequenced isolates
Having established a curated list of 1,325 mutations predict-
ive of resistance, we sought to develop a web-based tool to
rapidly identify a DST and strain-type profile. Our approach
called ‘TB Profiler’ ([34], Additional file 1: Figure S2) aligns
raw sequencing data to an abridged reference genome cov-
ering genomic regions of interest. The alignment is robust
to indels and genomic frameshifts, and can be completed in
minutes. Detection of M. tuberculosis lineage specific
markers was also incorporated [21]. In addition to identify-
ing known drug resistance associated mutations, the tool
also identifies other mutations in the candidate regions. TB
profiler processed fastq files at a linear rate of 80,000 se-
quence reads per second. Application to the 792 samples
led to the identification of 38 novel mutations (24 non-
synonymous SNPs, 9 indels and 5 intergenic SNPs) present
in phenotypically resistant strains but absent in susceptible
ones (Additional file 1: Table S4). All mutations were con-
firmed by the alignment of the short reads to the whole
H37Rv genome reference sequence using established gen-
ome analysis pipelines [21]. The median run-time for the
TB Profiler was 5 min (range, 2 to 10 min) across samples
with depth of coverage ranging from 20- to 1,000-fold. TB
Profiler can also be downloaded and run locally in a Unix
environment [37].
Discussion
The emergence and amplification of resistance to anti-
tuberculosis drugs has created a need for improveddetection tools to guide treatment options for patients
with MDR-TB, XDR-TB and post XDR (TDR-TB) dis-
ease. Molecular-based drug-susceptibility tests are more
rapid and microbiologically safe compared to phenotypic
assays. Nonetheless, rapid molecular assays are currently
limited. GeneXpert (Cepheid) tests only for rifampicin
resistance, the sensitivity of GenoType MTBDRplus
(Hain Life-Science) for the detection of isoniazid resist-
ance is reported to be approximately 80% to 90% [38,39]
and the GenoType MTBDRsl assay performs inad-
equately for fluoroquinolones, aminoglycosides and eth-
ambutol (reported sensitivities of 87% to 89%, 21% to
100% and 39% to 57%, respectively) [40,41]. Whole-
genome sequencing has the potential to determine the
full antibiogram if the genetic determinants of antibiotic
resistance are known [15-17,42]. However, M. tubercu-
losis sequencing has mainly been performed from cul-
tures and sequencing directly from clinical specimens
such as sputum still needs to be optimised. Compared to
Sanger sequencing that requires multiple sequencing
reactions to cover the various drug resistance loci,
whole-genome sequencing has the ability to characterise
all nucleotide positions in a single experiment. The
depth of next generation sequencing, where each loci is
examined numerous times (typically 100-fold coverage)
provides capacity to detect genetically mixed bacterial
populations (hetero-resistance) [43].
We have compiled and released a mutation library for
M. tuberculosis drug resistance [22]. By comparing in
silico drug resistance predictions to conventional pheno-
typic results, we have demonstrated that our library is
more accurate than current commercial molecular tests
and alternative mutation databases. Combining the muta-
tion library with a rapid detection tool for whole sequencing
data [34], we have demonstrated the potential for using next
generation sequencing for detecting drug resistance.
In silico validation of the mutation library demon-
strated high sensitivity for detecting resistance to RMP,
with the majority of resistance mutations found in a sin-
gle region of the rpoB gene [44]. Unsurprisingly, the mu-
tation analysis was less reliable for drugs with more
complex modes of action and where knowledge of the
genetic basis of resistance is less complete (for example,
PZA, ETH and EMB). Still, our curated library was more
accurate during in silico analysis for MDR and XDR-TB
than the commercial line probe assays, in addition to
assessing a greater number of drugs. Improved sensitiv-
ity was reported for INH, AMK, EMB, PZA and KAN
(Figure 2 and Additional file 1: Figure S3). The inferred
diagnostic performance from whole genome sequences
for the commercial tests may be overestimated, as in a
real scenario these tests have low detection limits and
are unable to differentiate synonymous from non-
synonymous amino acid changes [11].
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culture-based susceptibility testing methods, particularly
those for EMB and PZA, and the lack of a consensus
reference standard with which to compare new tests. Fu-
ture studies should be encouraged to adopt standardised
quantitative phenotypic assays [45]. DST is particularly
problematic for PZA [46] and false resistance results are
not uncommon [46]. The pncA gene (involved in resist-
ance to PZA) is one of the most polymorphic genes in
the M. tuberculosis genome and attempts to increase
sensitivity by including additional SNPs resulted in a re-
duction in specificity. Further work is needed to deter-
mine additional resistance polymorphisms, including
validation of putative markers with high quality pheno-
typic and clinical data. It should be noted that high posi-
tive predictive values are crucial for drug resistance tests
where the consequence of a false positive may be un-
necessary treatment with drugs of high toxicity and pro-
longed isolation in dedicated containment facilities.
Although an important increase in sensitivity was
achieved for EMB (88.7%), the specificity of 81.7% is
poor. These results concur with suggestions that degrees
of resistance to EMB may be acquired through muta-
tions in multiple loci, some of which are currently un-
known [47]. Although current knowledge does not allow
EMB resistance to be predicted with high precision,
known mutations may be used to identify strains predis-
posed to developing high-level resistance. Our results
demonstrate the considerable cross-resistance between
the fluoroquinolones. Minimal inhibitory concentrations
(MIC) can vary for these drugs and information on spe-
cific polymorphisms may influence dosing levels [48].
The poor specificity obtained for CAP and EMB may
be explained in terms of the high MIC used to classify
strains as clinically resistant or susceptible. Strains hav-
ing MIC values slightly below this cutoff have genetically
detectable resistance mechanisms but will falsely be
identified as susceptible [45,49]. Low specificity was also
obtained for MOX (68.7%) as opposed to that of OFX
(94.9%) using the same fluoroquinolones resistance
markers (that is, gyrA and gyrB mutations). Mutations in
gyrA and gyrB confer resistance to fluoroquinolones, al-
beit not at the same level, with MOX normally present-
ing the lowest MIC values in the group followed by
levofloxacin, in contract with the higher levels of resist-
ance observed for OFX and ciprofloxacin [50]. Strains
having the same fluoroquinolones resistance-conferring
mutations are therefore more likely to be regarded as
sensitive phenotypically (false positives) for MOX lead-
ing to lower specificity values. However, caution should
be exercised when considering the MOX data as few
phenotypic results were available and the uncertainty of
analysis is reflected in the wide confidence intervals
reported.The accuracy of the mutation analysis was observed to
vary by geographic region (Additional file 1: Figure S4).
Geographic disparities in the frequency of drug resistant
SNPs may reflect local treatment strategies and the
clonal nature of tuberculosis transmission and therefore
be the result of local microevolution. It has previously
been suggested that emergence of resistance in M. tuber-
culosis is associated with bacterial lineage. However,
such conclusions cannot be drawn from the present
study, as sampling strategies were not appropriate to
such analysis.
Not all drugs used in the treatment of tuberculosis
were included in this study. Drugs were omitted either
because insufficient susceptibility data were available
(that is, PAS, LZD, CFZ and BDQ) or because the mech-
anism of action remains obscure and SNPs to predict re-
sistance have yet to be systematically identified (for
example, cycloserine). A major advantage of the whole
genome approach is that all data are captured and add-
itional loci can easily be incorporated in the mutation li-
brary. Future work should assess the diagnostic accuracy
of drug resistance mutations identified for PAS, LZD,
CFZ and BDQ in clinical specimens.
Previous studies on discrepancies between mutation
and culture-derived resistant phenotypes suggest that
molecular assessment may eventually become the refer-
ence standard for some drugs [51,52]. We have demon-
strated rapid analysis of whole genome sequence data to
provide the genotype and predict resistance to 11 anti-
TB drugs. In the absence of whole genome sequencing
technology, which is still prohibitive in low-resource set-
tings, drug resistance markers can be detected using al-
ternative genotyping platforms, such as multiplex
ligation-dependent probe amplification (MLPA) assays
[53] or multiplexed oligonucleotides ligation PCR [54].
The presented curated database will facilitate the devel-
opment of more accurate molecular drug-susceptibility
tests.
Rapid determination of strain-specific and drug resist-
ance mutations will be beneficial for therapeutic selection,
clinical management of patients and implementation of
infection control measures. The free-to-use TB Profiler
prototype is available for a research setting, and further
studies are needed to assess its performance for clinical
use.
Conclusion
We have constructed an on-line software tool and meth-
odology that provides rapid analysis of genome sequence
data to describe the lineage of the M. tuberculosis strain
under test and predict resistance to 11 anti-TB drugs.
The tool refers to a library comprising 1,325 mutations
that is the most comprehensive and accurate such data
source yet reported. In addition to providing information
Coll et al. Genome Medicine  (2015) 7:51 Page 9 of 10about a greater number of drugs, a whole genome ap-
proach has the potential to improve detection sensitivity
for drugs such as isoniazid over the currently available
molecular tests. The ability to analyse raw sequence data
and extract information of clinical relevance in a few mi-
nutes would render whole genome analysis faster than
current phenotypic testing methods. Accelerated access
to tailored treatment could improve cure rates and re-
duce exposure to ineffective toxic drugs, improving the
patient experience and facilitating compliance. The ana-
lytical methodology described is flexible to allow moder-
ation of the library to encompass novel mutations and
incorporate new drugs should the need arise.
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